The international pharmaceutical supply-chain consortium Rx-360 held a launch meeting in Europe last week with more than 135 industry and regulatory representatives in attendance.
The international pharmaceutical supply-chain consortium Rx-360 held a launch meeting in Europe last week with more than 135 industry and regulatory representatives in attendance. According to an Rx-360 release, meeting participants focused on the global impact of counterfeit drug products and discussed the challenges involved in creating a nonprofit, voluntary consortium that will focus on shared supplier audits and disseminating supply-chain information and standards throughout the world. The consortium held a US-launch meeting for pharmaceutial and biotechnology companies, suppliers, and regulators in June 2009 in Washington, DC (see back story, Pharma Industry Consortium Rx-360 Tackles Supply-Chain Security.)
Another European-based initiative from the growing consortium is its new homepage widget featuring a searachable database of suppliers that have been certified by the European Directorate for the Quality of Medicines and Healthcare (EDQM). Established in 1994, the EDQM program specifically certifies the suitability of the monographs in the European Pharmacopoeia to adequately control the quality of a substance from the source.
Pharmaceutical Technology spoke to the director of EDQM, Susanne Keitel, and the head of Rx-360, Martin Van Trieste, among others, as part of a roundtable earlier this fall. The speakers’ full talks are available to listen to in podcast format on the PharmTech website.
See related PharmTech articles:
Is Industry Ready to Share Supplier Audits? Rx-360 Takes a Shot (blog post)
Sharing Supply-Chain Security (PharmTech November 2009 cover story)
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
2 Commerce Drive
Cranbury, NJ 08512